List view / Grid view
8 June 2016 | By Victoria White, Digital Content Producer
The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis...
8 June 2016 | By Victoria White, Digital Content Producer
Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
8 June 2016 | By Victoria White, Digital Content Producer
The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations...
8 June 2016 | By Victoria White, Digital Content Producer
The OPAL Beyond study met its primary efficacy endpoints demonstrating a statistically significant improvement with tofacitinib 5 mg BID and 10 mg BID...
7 June 2016 | By Victoria White, Digital Content Producer
The meningococcal vaccines market is expected to grow from around $1.1 billion in 2015 to $1.8 billion by 2025, according to GlobalData...
7 June 2016 | By Victoria White, Digital Content Producer
Using next-generation sequencing technology, researchers were able to study the genome of cancer cells, which is how they discovered the new cancer types...
7 June 2016 | By Victoria White, Digital Content Producer
BMS and MD Anderson are to collaborate to evaluate innovative strategies for the use of Opdivo and Yervoy to treat lung cancer patients...
7 June 2016 | By Victoria White, Digital Content Producer
The primary endpoint primary endpoint was a multicomponent measure evaluating improvement of physical function, cognitive function, and disability...
7 June 2016 | By Victoria White, Digital Content Producer
Epigallocatechin gallate, together with a cognitive stimulation protocol, might improve some cognitive domains in individuals with Down’s syndrome...
7 June 2016 | By Victoria White, Digital Content Producer
Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics...
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
7 June 2016 | By Victoria White, Digital Content Producer
Byvalson is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the US...
7 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma...
6 June 2016 | By Victoria White, Digital Content Producer
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency...
6 June 2016 | By Victoria White, Digital Content Producer
Immunocore has announced positive data from the first in human, Phase I clinical trial of its lead ImmTAC, IMCgp100...
